SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

IOL Chemicals & Pharmaceuticals informs about outcome of board meeting

17 May 2025 Evaluate
IOL Chemicals & Pharmaceuticals has informed that the Board of Directors in its meeting held on today 16th May 2025 has considered and approved: the Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March 2025. Ashwani & Associates, Chartered Accountants, the Statutory Auditors of the Company have issued Auditors' Reports with an Unmodified Opinion on the Financial Results of the Company for the Financial Year ended 31st March 2025. The Financial Results along with Auditors’ Report thereon, are enclosed as Annexure 1. Further, pursuant to Regulation 33(3)(d) of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Statutory Auditors, Ashwani & Associates, Chartered Accountants, have issued the Audit Reports on the Standalone and Consolidated Financial Results of the Company for the Financial Year ended 31st March 2025, with unmodified opinion; the re-appointment of Vikas Gupta as Joint Managing Director of the Company, subject to the approval of shareholders of the Company at their ensuing Annual General Meeting for a period of 5 years with effect from 29th May 2025. Vikas Gupta is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority; the appointment of B.K. Gupta & Associates, Practicing Company Secretaries, as Secretarial Auditors of the Company subject to the approval of shareholders of the Company at their ensuing Annual General Meeting for a term of 5 consecutive years from FY 2025-26 to FY 2029-30; the reconstitution of Audit Committees, Nomination & Remuneration Committee, Stakeholder’s Relationship Committee, Corporate Social Responsibility Committee and Risk Management Committee of the Board. The details of the Committees are given in Annexure 2.

The above information is a part of company’s filings submitted to BSE.

IOL Chem & Pharma Share Price

91.16 5.66 (6.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×